- Home
- KPRX vs LMFA Comparison
KPRX vs LMFA Comparison
Compare KPRX & LMFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- LMFA
- Stock Information
- Founded
- KPRX 1998
- LMFA 2008
- Country
- KPRX United States
- LMFA United States
- Employees
- KPRX N/A
- LMFA N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- LMFA Finance: Consumer Services
- Sector
- KPRX Health Care
- LMFA Finance
- Exchange
- KPRX Nasdaq
- LMFA Nasdaq
- Market Cap
- KPRX 8.3M
- LMFA 7.0M
- IPO Year
- KPRX N/A
- LMFA 2015
- Fundamental
- Price
- KPRX $3.18
- LMFA $1.45
- Analyst Decision
- KPRX Strong Buy
- LMFA Hold
- Analyst Count
- KPRX 1
- LMFA 1
- Target Price
- KPRX $10.00
- LMFA N/A
- AVG Volume (30 Days)
- KPRX 10.5K
- LMFA 35.4K
- Earning Date
- KPRX 05-09-2025
- LMFA 05-15-2025
- Dividend Yield
- KPRX N/A
- LMFA N/A
- EPS Growth
- KPRX N/A
- LMFA N/A
- EPS
- KPRX 0.87
- LMFA N/A
- Revenue
- KPRX $16,020,000.00
- LMFA $10,555,948.00
- Revenue This Year
- KPRX N/A
- LMFA $0.98
- Revenue Next Year
- KPRX N/A
- LMFA $4.31
- P/E Ratio
- KPRX $3.56
- LMFA N/A
- Revenue Growth
- KPRX N/A
- LMFA N/A
- 52 Week Low
- KPRX $2.51
- LMFA $1.02
- 52 Week High
- KPRX $5.76
- LMFA $6.11
- Technical
- Relative Strength Index (RSI)
- KPRX 55.96
- LMFA 56.46
- Support Level
- KPRX $2.64
- LMFA $1.11
- Resistance Level
- KPRX $3.25
- LMFA $1.50
- Average True Range (ATR)
- KPRX 0.19
- LMFA 0.13
- MACD
- KPRX 0.06
- LMFA 0.04
- Stochastic Oscillator
- KPRX 74.32
- LMFA 81.15
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About LMFA LM Funding America Inc.
LM Funding America Inc is a financial services company. The company provides funding to nonprofit community associations located in the state of Florida and to nonprofit community associations in the states of Washington and Colorado. Its products include Original Product and New Neighbor Guaranty. Its original product offering consists of providing funding to Associations by purchasing their rights under delinquent accounts that are selected by the Associations arising from unpaid Association assessments. It currently has two lines of business recently commenced cryptocurrency mining business and historical specialty finance business. The Company has two operating segments: Specialty Finance and Mining Operations, which generate the majority of its revenue.